Mylan N.V., a global pharmaceutical company, has launched bexarotene 75mg capsules in US, which is the generic version of Valeant's Targretin capsules. The product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Bexarotene 75mg capsules had US sales of approximately $155.5 million for the 12 months ending March 31, 2015, according to IMS Health.
Currently, Mylan has 270 ANDAs pending FDA approval representing $107.2 billion in annual brand sales, according to IMS Health. Forty-seven of these pending ANDAs are potential first-to-file opportunities, representing $33.3 billion in annual brand sales, for the 12 months ending December 31, 2014, according to IMS Health.
Subscribe to PharmaTutor News Alerts by Email >>
